#ADHD Therapeutics Market Analysis | Explore Tumblr posts and blogs

credenceresearchdotblog · 1 month ago

Text

The ADHD Drugs Market is projected to grow from USD 27,015 million in 2024 to an estimated USD 47,468 million by 2032, with a compound annual growth rate (CAGR) of 7.3% from 2024 to 2032.The Attention-Deficit/Hyperactivity Disorder (ADHD) drugs market has seen significant growth over the past decade, driven by rising awareness of the condition, improved diagnostic tools, and evolving treatment paradigms. ADHD, a neurodevelopmental disorder that affects children and adults, is characterized by inattention, hyperactivity, and impulsivity. With the increasing prevalence of ADHD and growing acceptance of medical interventions, the global market for ADHD drugs continues to expand.

Browse the full report https://www.credenceresearch.com/report/adhd-drugs-market

Market Dynamics

1. Growing Awareness and Diagnosis ADHD has become more widely recognized as a legitimate medical condition rather than a behavioral issue. This shift has led to earlier diagnosis and intervention, particularly in developed regions like North America and Europe. Advances in mental health education have further encouraged parents, teachers, and healthcare providers to seek professional assessments for children and adults exhibiting ADHD symptoms.

2. Pharmaceutical Innovations The market has seen a surge in innovative drug formulations, including extended-release capsules and non-stimulant alternatives. These advancements aim to improve patient compliance, reduce side effects, and provide tailored treatment options.

3. Rising Adult ADHD Diagnoses Historically, ADHD was considered a childhood disorder. However, recent studies reveal that ADHD persists into adulthood in many cases. As a result, there has been an increase in adult diagnoses and demand for treatment options tailored to this demographic.

4. Challenges in Market Growth - Stigma and Misdiagnosis: Despite growing awareness, stigma surrounding mental health continues to deter some individuals from seeking treatment. - Regulatory Hurdles: Stringent regulations for drug approval and concerns over the potential misuse of stimulant medications can delay market entry for new drugs. - Side Effects and Dependency Risks:** Some ADHD medications, particularly stimulants, are associated with side effects like insomnia, loss of appetite, and dependency risks, limiting their widespread use.

Future Trends

1. Digital Therapeutics Integration The integration of digital tools like ADHD-focused apps and behavior management platforms complements pharmacological treatments, enhancing overall care.

2. Personalized Medicine Advances in genetic research and pharmacogenomics are paving the way for personalized ADHD treatments, allowing medications to be tailored to individual patient profiles.

3. Non-Pharmacological Approaches Growing interest in non-pharmacological treatments, such as cognitive-behavioral therapy (CBT), dietary interventions, and neurofeedback, may impact the demand for medications.

Key Player Analysis:

Eli Lilly and Company.

Pfizer Inc.

Johnson & Johnson Services Inc.

Lupin

Novartis AG

Takeda Pharmaceutical Company Limited

Mallinckrodt Inc.

Purdue Pharma LP

NEOS Therapeutics Inc.

Supernus Pharmaceutical, Inc.

Segmentation:

Based on Product Type:

Stimulant Medications

Non-Stimulant Medications

Based on Technology:

Extended-Release Formulations

Non-Extended-Release Formulations

Digital Health Platforms

Drug Delivery Systems

Based on End-User:

Children • Adults • Adolescents

Based on Region:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report https://www.credenceresearch.com/report/adhd-drugs-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: [email protected]

Website: www.credenceresearch.com

0 notes

omkarpatel · 1 year ago

Text

Digital Therapeutics Market is Estimated to Witness High Growth Owing to Opportunity in Remote Patient Monitoring

Digital therapeutics are evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. These products incorporate advanced digital and mobile technologies to optimize disease management and treatment. Digital therapeutics provide tailored therapeutic interventions to patients through evidence-based techniques such as behavioural therapy, skills training, and more, improving clinical outcomes and reducing healthcare costs.

The global digital therapeutics market is estimated to be valued at US$ 6.6 Bn in 2023 and is expected to exhibit a CAGR of 20.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: Remote patient monitoring enables healthcare providers to remotely track patients' vital signs and symptoms using digital devices and sensors. This opportunity is estimated to drive significant growth in the digital therapeutics market over the forecast period. Remote patient monitoring allows healthcare providers to ensure treatment compliance, identify risk factors or worsening conditions, and provide timely interventions to patients at home. It avoids unnecessary visits to clinics or hospitals and reduces healthcare costs. With the increasing prevalence of chronic diseases and technological advancements, remote patient monitoring through digital therapeutics is expected to witness high demand in the coming years. Porter's Analysis Threat of new entrants: The digital therapeutics market has moderate threat from new entrants due to requirement of large investments and presence of established key players. Bargaining power of buyers: Buyers have low bargaining power due to specialized products and services offered by digital therapeutics. Bargaining power of suppliers: Digital therapeutics requires software and services from various suppliers. This gives moderate power to suppliers. Threat of new substitutes: Low threat as digital therapeutics offers solutions that cannot be easily substituted. Competitive rivalry: High as major players compete on basis of innovations, targeted solutions and services. SWOT Analysis Strength: Personalized treatment solutions, affordable care, improved accessibility and user engagement are key strengths. Weakness: Data privacy and security concerns, lack of awareness and high upfront costs are weaknesses. Opportunity: Growing geriatric population, rise in chronic diseases, and government support present opportunities. Threats: Resistance from healthcare providers, interoperability issues and regulatory challenges are threats. Key Takeaways The global digital therapeutics market is expected to witness high growth at a CAGR of 20.5% during the forecast period of 2023-2030. The global digital therapeutics market is estimated to be valued at US$ 6.6 Bn in 2023 and is expected to exhibit a CAGR of 20.5% over the forecast period 2023-2030. Regional analysis indicates North America holds the largest share currently. Factors such as advanced healthcare infrastructure, growing awareness about digital therapeutics and presence of major players is driving growth. However, Asia Pacific region is expected to grow at fastest pace with 25% CAGR during the forecast period. Increasing healthcare expenditures, large patient population and growing acceptance of new technologies are factors influencing growth. Key players operating in the digital therapeutics market include Happify, Inc., 2Morrow, Inc., Akili Interactive Labs, Inc., Click Therapeutics, Inc., and Fitbit, Inc. Major players are focused on developing innovative solutions to expand their presence. For instance, Akili Interactive Labs has developed a digital therapy to improve cognitive function in children with ADHD.

#healtcare

0 notes

sapanas · 4 years ago

Text

ADHD Therapeutics Market Share, Growth By Top Company, Application, Driver, Trends & Forecasts By 2027

ADHD Therapeutics Market Overview

Attention Deficit Hyperactivity Disorder, majorly known as ADHD is a neuro-developmental condition that mostly occurs in the childhood and continues in adulthood if not treated in time. Symptoms of ADHD include combinations of tenacious issues such as impulsive behavior, difficulty in sustaining attention, and hyperactivity, etc.

The exact cause leading to the occurrence of ADHD is not known. However, some environmental factors such as premature birth, prenatal tobacco exposure, and genetics are considered as severe risk factors for ADHD. Similarly, there is no breakthrough treatment for ADHD, but early detection & treatment can help patients to manage their conditions.

Over the past few years, the global ADHD therapeutics market has been growing rapidly, mainly due to the growing prevalence of ADHD and the advancements in the therapeutics to manage its conditions. The increasing uses of ADHD medicines indicate that the numbers of patients being diagnosed and treated have been increasing.

Considering the traction, the market is vibrating with; Market Research Future (MRFR) in its recently published study report asserts that the global ADHD therapeutics market gaining further prominence will register a spectacular growth along with a striking CAGR throughout the forecast period (2017 – 2024).

Obtain Premium Research Report Details @ https://www.marketresearchfuture.com/reports/adhd-therapeutics-market-1573

The burgeoning healthcare sector along with the increasing number of advanced care providing facilities substantiates the market growth. However, the number of patients receiving the quality treatment, worldwide, is yet far little. In few of the developing regions, ADHD is still under-diagnosed and remains untreated often.

The well-established ADHD therapeutics market perceives several options available for diagnosis and treatments, ranging from behavioral intervention and prescription medication to digital medicines. Additionally, there are antibiotics developed with technological interventions to provide preferable outcomes.

Spreading awareness among people about the disorder and the availability of various therapeutics to treat its conditions is a key factor fostering market growth. Evidently, improving economic conditions worldwide act as a major tailwind pushing up the market growth by availing improved healthcare.

Conversely, factors such as incidents of drug resistance, unmet clinical needs, and the high cost associated with the treatments are likely to impede the market growth. However, emerging Biosimilars are expected to support market growth, availing affordable, cost-effective medical products.

ADHD Therapeutics Market - Segmentations

MRFR has segmented the report into three key dynamics for an easy grasp;

By Drug Type : Stimulants, Non-stimulants and others.

By Distribution Channel : Hospitals, Pharmacies, Clinics, and Research Laboratories among others.

By Regions : Asia Pacific, Europe, North America, and Rest-of-the-World (RoW).

ADHD Therapeutics Market - Regional Analysis

The North American region accounts for the leading market for ADHD therapeutics, Globally. The ADHD therapeutics market in this region commands the largest market share, followed by Europe & Asia Pacific market, respectively. The US ADHD therapeutics market heading with the high healthcare expenditure leads the regional market. Continuing with the same growth trends in the future, North America is expected to retain its dominance over the global ADHD therapeutics market, creating a large revenue pocket throughout the forecast period.

Heading with the significant technological advancements and the emergence of digital medicines, the ADHD therapeutics market in the European region holds the second position in terms of the size. Moreover, the presence of a flourishing medical devices market and rising healthcare expenditure in the region are estimated to facilitate the growth of the market.

The Asia Pacific ADHD therapeutics market is emerging as a lucrative market, worldwide. The factors substantiating the market growth include the huge population, large unmet needs, and the availability of low-cost drugs for ADHD treatment. Besides, the improving economic conditions in the region are acting as a key driving force pushing up the market growth by boosting the healthcare sector.

Increasing funding support from the public and private bodies are supporting the market growth in the region, increasing R&D activities. Furthermore, the rising penetration of healthcare insurance mainly in the countries such as Malaysia, Thailand, and Vietnam alongside the availability of new treatment methods that are increasingly meeting the growing demand for the treatments is expected to drive the ADHD therapeutics market in the in the Asia Pacific region.

Global ADHD Therapeutics Market - Competitive Analysis

The highly competitive, ADHD therapeutics market appears to be fragmented characterized by the presence of various large and small-scale players. Well-established players incorporate strategic initiatives such as acquisition, partnership, collaboration, expansion, and product launch to gain a competitive edge and to maintain their positions in the market.

ADHD Therapeutics Market Key Players:

Key players leading the global ADHD therapeutics market include Concordia International Corp., Highland Therapeutics Inc., Eli Lilly and Company, Janssen Global Services LLC, Novartis AG, NEOS Therapeutics Inc., Noven Pharmaceuticals Inc., Teva Pharmaceutical, Shire, and Pfizer Inc. among others.

ADHD Therapeutics Industry/Innovations/Related News:

January 04, 2019 – Researchers at Children's Hospital of Philadelphia (US) published the results of the study wherein they evaluated a digital medicine tool – EVO designed for investigational treatment for children with autism spectrum disorder (ASD) and co-occurring attention/deficit-hyperactivity disorder (ADHD). The outcomes published in the Journal of Autism and Developmental Disorders confirmed the acceptability, feasibility, and safety of EVO designed by Akili Interactive, a prescription digital medicine company. EVO delivers sensory and motor stimuli through an action video game experience.

#ADHD Therapeutics Market #ADHD Therapeutics Market Size #ADHD Therapeutics Market Share #ADHD Therapeutics Market Growth #ADHD Therapeutics Market Analysis

0 notes

industryinsights · 3 years ago

Text

ADHD Therapeutics Market Size, Revenue Analysis, Opportunities, Trends, Forecast Till 2027

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder with a group of behavioral symptoms that include hyperactivity, inattentiveness and impulsiveness. The symptoms of ADHD begin in childhood and can continue through adolescence and adulthood. As per the report published by Market Research Future (MRFR), the global ADHD therapeutics market is registered to grow steadily till the end of 2024.

Market Drivers and Restraints:

The symptoms of ADHD such as lack of attention, hyperactivity and impulsivity hamper proper functioning and development of an individual. Increasing awareness regarding neurodevelopmental disorders and easy availability of diagnostic guidelines over the internet is projected to boost the growth of the global ADHD therapeutics market.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1573

Changing lifestyles and value systems along with the factors like genetic inheritance and premature birth are resulting to the rise in prevalence of ADHD among children in the age group of 4-17 years, which in turn is propelling the growth of the global ADHD therapeutics market. Increasing availability of online platforms for therapists that assure anonymity of the patient is inclining more individuals towards undergoing therapeutic treatment for ADHD, which in turn is fueling the expansion of the global ADHD therapeutics market

However, underdiagnosis of ADHD due to the existence of comorbid conditions in children, lack of awareness and low availability of non-stimulant drugs to treat ADHD in various regions are likely to hamper the expansion of the global ADHD therapeutics market during the forecast period.

Market Segmentation:

The global ADHD therapeutics market has been segmented on the basis of drug type and distribution channel. Based on drug type, the ADHD therapeutics market is segmented into stimulants and non-stimulants. The stimulants segment is sub-segmented into amphetamine, methylphenidate, dextroamphetamine, lisdexamfetamine and others. The non-stimulants segment is sub-segmented into atomoxetine, bupropion, guanfacine and clonidine

Based on distribution channel, the ADHD therapeutics market is segmented into hospitals, clinics, pharmacies, research laboratories and others.

Regional Analysis:

Geographically, the global ADHD therapeutics market is segmented into four major regions such as North America, Europe, Asia Pacific and the Middle East and Africa. The ADHD therapeutics market in the North America region accounts for the dominant share in the global ADHD therapeutics market owing to the increasing prevalence of ADHD in the children and high healthcare expenditure by the population in this region. The ADHD therapeutics market in the Europe region is projecting significant growth owing to the increased research and development for the introduction of more effective drugs in this region. The Asia Pacific region is anticipated to grow at a notable pace in the coming years due to increased awareness regarding ADHD and its available treatments. Whereas, the Middle East and Africa region is projecting steady growth in the global ADHD market owing to the low awareness and poor primary health care in the underdeveloped areas of this region.

Industry Updates:

In August 2018, Ironshore Pharmaceuticals & Development, Inc., a subsidiary of Highland Therapeutics Inc., has received FDA approval for the New Drug Application for Jornay PM (methylphenidate) which was formerly known as HLD200 which is used for the treatment of ADHD in patients of the age six and older

In August 2018, FDA has issued a Complete Response Letter (CRL) to Sunovion Pharmaceutical asking for further clinical data to evaluate the efficacy of dasotraline, the ADHD drug.

Key Players:

The prominent players profiled by MRFR in the report on the global ADHD therapeutics market are Concordia International Corp., Eli Lilly and Company, Highland Therapeutics Inc., Janssen Global Services LLC, NEOS Therapeutics Inc., Novartis AG, Noven Pharmaceuticals Inc., Pfizer Inc., Shire, Teva Pharmaceutical and others.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/adhd-therapeutics-market-1573

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Have a Look at Related Reports:

Healthcare Analytics Market - https://www.globenewswire.com/en/news-release/2019/07/26/1892202/0/en/Healthcare-Analytics-Market-to-Witness-Steady-Growth-at-27-1-CAGR-During-2019-2024-Increasing-Adoption-of-Technological-Advancements-Boost-the-Growth-of-Global-Healthcare-Analytics.html

Healthcare Mobility Solutions Market - https://www.globenewswire.com/en/news-release/2019/07/26/1892136/0/en/Healthcare-Mobility-Solutions-Market-Boost-by-Increasing-Medical-Needs-High-Demand-Latest-Advancements-Current-Trends-and-End-User-Approch-Towards-Healthcare-Services.html

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: [email protected]

1 note · View note

researchinhealthcare · 3 years ago

Text

ADHD Therapeutics Global Market Research Report 2021 Professional Edition 2021 Market Size, Share, Company Profiles, Trends, Segment Demand for Forecast through 2027

ADHD Therapeutics Market Overview :

Attention deficit hyperactivity disorder, or commonly known as ADHD, is an issue that mostly occurs in children. Its is a neurodevelopmental disorder which often lasts till adulthood. The global ADHD therapeutics market is expecting a rise by considerable 6.8% CAGR during the forecast period (2016-2024). As its symptoms, children can display signs of attention deficiency, troubled impulsive behaviors or being hyperactive. In children, paying attention is a problem that wanes with age but those who have this disorder seems to carry it all along. The market was valued at approximately USD 19.7 billion in 2018

The ADHD therapeutics market is depending a lot on the rising prevalence of the disorder. The advancement in technologies can now provide several options for treatments which with growing awareness regarding the issue can provide traction to the market growth. At the same time, the ADHD therapeutics market is getting much more benefits from cognitive therapies and change in dietary plans. With the advents in nutrients, the ADHD therapeutics market could drastically transform in the coming years. However, comorbid conditions exhibited by children can restrain physicians from having a sound diagnosis owing to which the ADHD therapeutics market can get bogged down. In many countries, necessary drugs are not available and that can be a hindrance.

ADHD Therapeutics Market Segmental Analysis :

MRFR’s identifies segments in the global ADHD therapeutics market by drug type and distribution channel. The report carries detailed analysis of volume-wise and value-wise data that would substantiate the market position. Also, it would reveal growth opportunities that would simplify market capitalization.

Based on the drug type, the ADHD therapeutics market includes stimulants and non-stimulants. The stimulants segment comprises lisdexamfetamine, amphetamine, methylphenidate, dextroamphetamine, and others. The non-stimulants segment encompasses guanfacine, bupropion, atomoxetine, and clonidine.

By distribution channel, the ADHD therapeutics market includes hospitals, clinics, pharmacies, research laboratories and others. The research laboratories segment is doing substantially good owing to the increase in investment.

Click For Sample Copy of ADHD @ https://www.marketresearchfuture.com/sample_request/1573

ADHD Therapeutics Market Regional Analysis :

Mapping the global ADHD therapeutics market reveals an inclusion of four major regions, namely, North America, Europe, Asia Pacific (APAC) and the Middle East & Africa (MEA). MRFR in its report made a thorough analysis of patient numbers and impact that can be incorporated by new and existing therapeutics. The process amplified even the minutest details for better understanding.

Superior healthcare structure, better awareness, and constant evolving in countering a disease are factors giving the North American market a better chance to fight. The regional market is dominating the global counterpart. At the same time, the number of children suffering from ADHD is rising owing to several factors. With high expenditure capacity, the regional market is getting amply backed up by cases getting registered for treatment.

Europe’s market is also enjoying similar benefits due to features that reflect the North American market structure. At the same time, the scope in research and development sector is pushing the boundary wider for further growth opportunity. The APAC region is getting substantial traction in recent times owing to the revamped healthcare structure and increasing awareness that is ensuring a hike in the number of cases getting registered. Availability of treatment is also becoming easier due to which the growth opportunity for the market is quite promising. Whereas, the MEA region can record a steady growth owing to the lack in awareness and poor healthcare provisions.

ADHD Therapeutics Market Competitive Landscape :

Several companies in the global ADHD therapeutics market are performing in a ground-breaking manner by following strategies that would inspire individual growth and ensure holistic growth for the market. These companies are Teva Pharmaceutical, Concordia International Corp., Novartis AG, Highland Therapeutics Inc., Eli Lilly and Company, NEOS Therapeutics Inc., Janssen Global Services LLC, Pfizer Inc., Shire, Noven Pharmaceuticals Inc., and others.

In April 2019, FDA cleared the use of first medical device for non-medicinal treatment of ADHD, Monarch external Trigeminal Nerve Stimulation (eTNS) System. The device is meant for kids between 7 and 12 years suffering from ADHD. The device is intended for homecare segment and is to be used strictly under a caregiver.

Updated Analysis Report Info @ https://www.marketresearchfuture.com/reports/adhd-therapeutics-market-1573

#ADHDTherapeuticsMarketResearch #ADHDTherapeuticsmarketanalysis #ADHDTherapeuticsindustryanalysis #ADHDTherapeuticsresearchreports #ADHDTherapeuticsresearchcompany #Attention-DeficitHyperactivityDisorderTherapeuticsMarket

1 note · View note

pranalipawarshinde · 3 years ago

Text

Disruptive Behavior Disorders Market is Set to Grow According to Latest Research Report by 2031

Global Disruptive Behavior Disorders Market: Snapshot

Rise in the prevalence of behavioral disorders among children and youth population across the globe is estimated to drive the sales growth in the global disruptive behavior disorders market during the forecast period of 2021 to 2031. Conduct disorder (CD), oppositional defiant disorder (ODD), and attention deficit hyperactivity disorder (ADHD) are some of the key behavioral disorders.

An upcoming report by Transparency Market Research (TMR) provides bird’s-eye view of the global disruptive behavior disorders market. Hence, it delivers exhaustive assessment of vital facets such as growth drivers, current and historical trends, growth restraints, R&D activities, growth opportunities, and challenges in the market for disruptive behavior disorders. Therefore, the report works as a valuable guide to gain all crucial data on the disruptive behavior disorders market for the forecast period of 2021 to 2031.

Report Overview: https://www.transparencymarketresearch.com/disruptive-behavior-disorders-market.html

The TMR report on the global disruptive behavior disorders market is presented in the form of segments, which are dependent on several important parameters including type, application, and region. In terms of application, the disruptive behavior disorders market is divided into three main parts, namely, personal use, hospital, and clinic.

Key Drivers of Disruptive Behavior Disorders Market Growth

Disruptive disorder refers to an undesirable behavior such as high temper, disagreements, and aggressive behavior in an individual. This health disorder is more commonly found in children and teenagers, notes a TMR study on the global disruptive behavior disorders market. The complexity of these disorders can be minimized if a patient is provided treatment in the early stage of the disease.

Several medical institutes and hospitals around the world are increasing efforts to spread awareness about such types of disorders. Hence, they are seen organizing varied campaigns that highlight different treatment solutions available for such conditions. These efforts are fueling the growth avenues in the disruptive behavior disorders market.

The disruptive behavior disorders market is estimated to gain promising growth opportunities in the upcoming years owing to increase in awareness on behavior disorders and available treatment solutions. Furthermore, the market for disruptive behavior disorders is anticipated to bolster in the upcoming years owing to a rise in the prevalence of substance abuse across the globe.

Request Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4752

Competition Landscape of Disruptive Behavior Disorders Market

The nature of the global disruptive behavior disorders market seems to be fairly fragmented. Due to presence of several well-established companies, the competition landscape of the market for disruptive behavior disorders is highly intense. Hence, companies in the market are executing organic and inorganic strategies such as joint ventures, partnerships, mergers, acquisitions, and collaborations in order to stay ahead of the competition.

Players operating in the global disruptive behavior disorders market are increasing their researches in order to develop highly effective treatment solutions. These efforts are estimated to drive promising growth avenues in the global disruptive behavior disorders market during the forecast period.

The list of key companies operating in the global disruptive behavior disorders market includes:

DURECT Corporation

Eli Lilly

Bionomics ltd

Chelsea therapeutics

Johnson & Johnson

Pfizer

Pre Book: https://www.transparencymarketresearch.com/checkout.php?rep_id=4752&ltype=S

Regional Analysis of Disruptive Behavior Disorders Market

On the basis of region, the global disruptive behavior disorders market shows presence in many regions such as Middle East and Africa, Europe, Latin America, Asia Pacific, and North America. Of all regions, North America is one of the lucrative regions for enterprises operating in the market for disruptive behavior disorders. The growth of the North America disruptive behavior disorders market is ascribed to rise in the prevalence of behavioral disorders among regional populace.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/elderly-and-disabled-assistive-devices-market-to-expand-at-cagr-of-5-3-during-forecast-period-notes-tmr-study-301467249.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

0 notes

bearni · 3 years ago

Text

Global Attention Deficit Hyperactivity Disorder (ADHD) Market By Type (Stimulants,Non-Stimulants), By Application (Specialty ClinicsHospitalRetail), By Country, and Manufacture - Industry Segment, Competition Scenario and Forecast by 2029

Industry analysis and future outlook on Attention Deficit Hyperactivity Disorder (ADHD) Global Market brings a systematic perspective of the market execution and assists in strategic decision making for worldwide and additionally the regional situation. Detailed sections provides in-depth arrangement, the Attention Deficit Hyperactivity Disorder (ADHD) contemplate that make sense of different perspectives relating to the global market. To begin with, the Attention Deficit Hyperactivity Disorder (ADHD) market definition, applications, arrangement, and industry esteem chain structure are incorporated into the answer, to target gathering of people on restricting Attention Deficit Hyperactivity Disorder (ADHD) market elements including drivers, limitations, openings, patterns, applications, topographical/local Attention Deficit Hyperactivity Disorder (ADHD) markets, and aggressive scene.

Global Attention Deficit Hyperactivity Disorder (ADHD) Industry Market was valued at USD XX Million in the year 2020. The market is further estimated to grow at a CAGR of XX% from 2020 to reach USD XX Million by the year 2029.

Get Quick Free Sample Brochure report at: https://www.globalresearchview.com/report/global-attention-deficit-hyperactivity-d/GRV52885/request-sample/

Attention Deficit Hyperactivity Disorder (ADHD) market rivalry by top makers/players, with Attention Deficit Hyperactivity Disorder (ADHD) deals volume, Value (USD/Unit), Revenue (Mn/Bn USD) and market size for every producer/player; the significant players include:

Takeda Neos Therapeutics Eli Lilly Pfizer Alcobra Supernus Pharmaceuticals Noven Pharmaceuticals Novartis Johnson & Johnson Curemark

Worldwide Attention Deficit Hyperactivity Disorder (ADHD) statistical surveying report uncovers that the Attention Deficit Hyperactivity Disorder (ADHD) business will develop with pivotal CAGR over the estimated forecast period of 2021 and 2029. The global Attention Deficit Hyperactivity Disorder (ADHD) market in forecast years 2021-2029, is expected to hit Mn/Bn$ XX USD by 2029. The Attention Deficit Hyperactivity Disorder (ADHD) market gives broad development openings over the both created and creating economies. Further, the Attention Deficit Hyperactivity Disorder (ADHD) business sectors could profit without a doubt from the expanding interest to bring down Attention Deficit Hyperactivity Disorder (ADHD) expenses of treatment over the globe.

Inquiry for Buying report to get customization at: https://www.globalresearchview.com/report/global-attention-deficit-hyperactivity-d/GRV52885/inquiry

Key Highlights of the Report:

Attention Deficit Hyperactivity Disorder (ADHD) Market Report provides forecast and industry outlook for the period of 2021-2029 with 2020 as the base year and covering historic data for years 2015-2019.

Attention Deficit Hyperactivity Disorder (ADHD) Market outlook with Porter’s 5 Forces Analysis will provide market dynamics (Drivers, Restraints, Opportunities & Threats).

Attention Deficit Hyperactivity Disorder (ADHD) Competitive landscape section gives you the competitive edge over other key players in the market (Key Business Strategies, Recent Development M&A, Company Overview, Products/Services Portfolio & Financial Overview).

Attention Deficit Hyperactivity Disorder (ADHD) Technological Scenarios & Expected Developments.

Attention Deficit Hyperactivity Disorder (ADHD) End-Use Industry & Consumer Behaviour Trends.

Attention Deficit Hyperactivity Disorder (ADHD) Export-Import Scenario.

Attention Deficit Hyperactivity Disorder (ADHD) Regulatory Policies across each region.

Attention Deficit Hyperactivity Disorder (ADHD) In-depth analysis on Industry Trends & Dynamics across each segment covered in the report.

Based on Type, Attention Deficit Hyperactivity Disorder (ADHD) market report shows development rate of each type, covers:

Stimulants Non-Stimulants

End clients/applications, Attention Deficit Hyperactivity Disorder (ADHD) market report centers around the status and viewpoint for best applications/end clients, development rate for every application, this can be isolated into:

Specialty Clinics Hospital Retail

Access More Information at: https://www.globalresearchview.com/report/global-attention-deficit-hyperactivity-d/GRV52885

In conclusion, the global Attention Deficit Hyperactivity Disorder (ADHD) industry report unveils research finding, outcomes, conclusions. Likewise, disclose various Attention Deficit Hyperactivity Disorder (ADHD) data sources, traders/vendors, suppliers, manufacturers, sales channel, and addendum. In short, the overall Attention Deficit Hyperactivity Disorder (ADHD) report is a lucrative document for people implicated in Attention Deficit Hyperactivity Disorder (ADHD) market.

Global Impact of COVID-19 Analysis:

COVID19 is an unrivaled global public health emergency that affects almost every industry, so the projected long-term impact will affect industry growth over the forecast period. The report provides insights into COVID19, taking into account changes in consumer behavior and demand, purchasing behavior, supply chain diversion, the dynamics of current market forces, and significant government intervention. Insights, analysis, estimates and forecasts considering the impact of COVID19 on the market.

About Us:

GlobalResearchView (GRV) is one of the leading market research company which aims to serve the most excellent research to the various sectors of business. We are prominent in satisfying all kinds of market research needs.

Contact US:

Jennifer Da (Head Global Business Development) – Global Research View(GRV) 701, Milton Avenue, East Ham,London. United kingdom. Pincode - 4E6 1BN Email: [email protected] Websites: www.globalresearchview.com Tel: +44 020 8638 7098

#Global Attention Deficit Hyperactivity Disorder (adhd) Market World Attention Deficit Hyperactivity Disorder (adhd) Market Europe Attentio

0 notes

industryinsights · 3 years ago

Text

ADHD Therapeutics Market Analysis, Revenue Share, Company Profiles, Launches, & Forecast Till 2027

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder with a group of behavioral symptoms that include hyperactivity, inattentiveness and impulsiveness. The symptoms of ADHD begin in childhood and can continue through adolescence and adulthood. As per the report published by Market Research Future (MRFR), the global ADHD therapeutics market is registered to grow steadily till the end of 2024.

Market Drivers and Restraints:

The symptoms of ADHD such as lack of attention, hyperactivity and impulsivity hamper proper functioning and development of an individual. Increasing awareness regarding neurodevelopmental disorders and easy availability of diagnostic guidelines over the internet is projected to boost the growth of the global ADHD therapeutics market.

Changing lifestyles and value systems along with the factors like genetic inheritance and premature birth are resulting to the rise in prevalence of ADHD among children in the age group of 4-17 years, which in turn is propelling the growth of the global ADHD therapeutics market. Increasing availability of online platforms for therapists that assure anonymity of the patient is inclining more individuals towards undergoing therapeutic treatment for ADHD, which in turn is fueling the expansion of the global ADHD therapeutics market

However, underdiagnosis of ADHD due to the existence of comorbid conditions in children, lack of awareness and low availability of non-stimulant drugs to treat ADHD in various regions are likely to hamper the expansion of the global ADHD therapeutics market during the forecast period.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1573

Market Segmentation:

The global ADHD therapeutics market has been segmented on the basis of drug type and distribution channel. Based on drug type, the ADHD therapeutics market is segmented into stimulants and non-stimulants. The stimulants segment is sub-segmented into amphetamine, methylphenidate, dextroamphetamine, lisdexamfetamine and others. The non-stimulants segment is sub-segmented into atomoxetine, bupropion, guanfacine and clonidine

Based on distribution channel, the ADHD therapeutics market is segmented into hospitals, clinics, pharmacies, research laboratories and others.

Regional Analysis:

Geographically, the global ADHD therapeutics market is segmented into four major regions such as North America, Europe, Asia Pacific and the Middle East and Africa. The ADHD therapeutics market in the North America region accounts for the dominant share in the global ADHD therapeutics market owing to the increasing prevalence of ADHD in the children and high healthcare expenditure by the population in this region. The ADHD therapeutics market in the Europe region is projecting significant growth owing to the increased research and development for the introduction of more effective drugs in this region. The Asia Pacific region is anticipated to grow at a notable pace in the coming years due to increased awareness regarding ADHD and its available treatments. Whereas, the Middle East and Africa region is projecting steady growth in the global ADHD market owing to the low awareness and poor primary health care in the underdeveloped areas of this region.

Industry Updates:

In August 2018, Ironshore Pharmaceuticals & Development, Inc., a subsidiary of Highland Therapeutics Inc., has received FDA approval for the New Drug Application for Jornay PM (methylphenidate) which was formerly known as HLD200 which is used for the treatment of ADHD in patients of the age six and older

In August 2018, FDA has issued a Complete Response Letter (CRL) to Sunovion Pharmaceutical asking for further clinical data to evaluate the efficacy of dasotraline, the ADHD drug.

Key Players:

The prominent players profiled by MRFR in the report on the global ADHD therapeutics market are Concordia International Corp., Eli Lilly and Company, Highland Therapeutics Inc., Janssen Global Services LLC, NEOS Therapeutics Inc., Novartis AG, Noven Pharmaceuticals Inc., Pfizer Inc., Shire, Teva Pharmaceutical and others.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/adhd-therapeutics-market-1573

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Have a Look at Related Reports:

Catheters Market - https://icrowdnewswire.com/2020/12/31/catheters-market-size-is-projected-to-reach-usd-49-73-billion-at-a-6-14-cagr-by-2023/

Inhalation Anesthesia Market - https://icrowdnewswire.com/2020/12/31/inhalation-anesthesia-market-sales-insights-growth-projection-research-insights-business-overview-and-covid-19-impact-analysis-by-2025/

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: [email protected]

0 notes

fostermarketarch · 4 years ago

Text

Important Thing Need To Know About Upcoming Medical Foods Market In 2027

Medical foods are foods that are specially formulated and intended for the dietary management of a disease that has distinctive nutritional needs that cannot be met by normal diet alone. Growing health disorders in patients such as metabolism disorders, gastrointestinal disorders, neurological, and psychological disorders are generating the demand for medical foods across the globe. Further people are shifting their preferences towards healthy food which is propelling the market growth.

Medical foods are not required to undergo premarket review or approval by FDA. Additionally, they are exempted from the labeling requirements for health claims and nutrient content claims under the Nutrition Labeling and Education Act of 1990. In 2016 the FDA published an update: Guidance for Industry: Frequently Asked Questions About Medical Foods; Second Edition. Definitions and labeling requirements are included.

Get Free PDF Brochure of this Market @https://www.fostermarketresearch.com/product/industry/9/179/Pdf%20Brochure/

Competitive Landscape:

Key players in the global medical foods market include: Abbott Laboratories, Nestle S.A., Alfasigma spA, Targeted Medical Pharma Inc., Cerecin Inc., Ironshore Pharmaceuticals & Development, Inc., Primus Pharmaceuticals, Inc., Danone S.A., Fresenius Kabi AG, Reckitt Benckiser Group plc, and Metagenetics, Inc. among others.

Key Insights:

Latest Updates

Analyst Views

Future Outlook of the Market

The industry players have adopted innovative growth strategies including new product development, and partnership to increase their market share and strengthen their position. For instance, in June 2019, Ironshore Pharmaceuticals & Development, Inc. launched the Journal PM (methylphenidate HCl) capsule, which is approved by the FDA for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) patients. This capsule acts as a central nervous system stimulant. This strategy enabled the company to strengthen its position with an innovative product launch.

Market Taxonomy:

By Ingredients

Proteins

Vitamins Minerals

Isoflavones

Omega-3

Phytosterols

By Formulation

Powder

Tablet/Capsules

Others

By Route of Administration

Oral

Enteral

By Application

Diabetic

Nutritional Deficiency

Alzheimer’s Diseases

Attention Deficit Hyperactivity Disorder (ADHD)

Depression

Neuropathy

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

For More Information of this Market @https://www.fostermarketresearch.com/product/industry/9/179/

Market Dynamics:

Medical food consumption is increasing annually due to rising various deficiencies and disorders in people across the world. Lack of proper dietary food and adoption of unhealthy lifestyles causing the demand for medical foods. Medical foods provide patients an effective therapeutic remedy for managing sleep, pain, and cognitive disorders without any critical risks. It is an important and complementary category of healing agents for addressing disease in a nutritional way.

During the COVID-19 pandemic situation, consumers have become more conscious about their health and immunity system which is reflecting increasing demand for nutritional medical foods from several areas of the world. Medical experts are suggesting multi-nutrient medical foods for old age people to reduce the chances of infection by increasing their immunity level. Owing to such reasons, medical food manufacturers such as Reckitt Benckiser Group plc are increasing their efforts to offer products for boosting consumer immunity.

Benefits You Gain With Our Research Methodology:

Develop your Business strategies to refine the profits in near team.

Grow your Business profit ratio through our analytics report.

Acquire the valuable insights on different products, services and technology along with their obsolescence nature in the foreseen period.

Gain and upper hand on competition by having competitive financial, growth and economic data.

Identity future threats by our accurate forecasting strategies.

Obtain Go-To market strategy to increase your chances in the existing market.

Key highlights from Covid-19 impact assessment:

Implications of Covid-19 on the global economy.

Disruptions in supply chain.

Peaks and valleys in demand share.

Immediate and projected outlook of the pandemic on business development.

Buy Now This Business Strategic Report to Improve Your Profits @ https://www.fostermarketresearch.com/product/buy/9/179/

About Foster Market Research:

Foster Market Research is a global market intelligence and advisory firm engaged in providing data-driven research extract from rigorous analysis, to the clients to make critical business decisions and execute them successfully. Foster connects over various distribution channels and numerous markets for great understanding of the trends and market to deliver our clients with accurate data.

Our focus is on providing market research that delivers a positive impact on your business. We work continuously to provide our clients with the most accurate analytics data and research reports without any delay so as to improve their business strategies and provide them with rich customer experience.

Contact Us:

1701 Royal Lane, #1306, Dallas Tx-75229 Phone: +1 469 4981929 Email: [email protected]

0 notes

healthcare-market · 4 years ago

Text

Rare Neurodegenerative Disease Treatment Market Examined in New Research Report

Rare Neurodegenerative Disease Treatment Market: Introduction

According to the report, the global rare neurodegenerative disease treatment market was valued at US$ 67 Bn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030. Various types of neurological disorders are epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cerebrovascular diseases, and others. The different types of drug class to treat neurology disorders are anticholinergic, antiepileptic, antipsychotic, hypnotic & sedative, analgesics, antihypertensive, anticoagulants, and others. In terms of indication, the global rare neurodegenerative disease treatment market has been classified into multiple sclerosis (MS), Alzheimer’s disease, Parkinson's disease, acute migraine, autism, narcolepsy, amyotrophic lateral sclerosis (ALS), attention deficit hyperactivity disorder (ADHD), spinal muscular atrophy, Tourette syndrome, Huntington's disease, and others. The multiple sclerosis (MS) segment captured the largest market share in 2019. The segment is expected to be driven by rise in number of patients with multiple sclerosis and increase in awareness about the disorder.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78468

Based on drug class, the global rare neurodegenerative disease treatment market has been categorized into neurotransmitter agents, neuroprotective agents, biologics, and others. The neuroprotective agents segment held major share of the global market in 2019. In terms of distribution channel, the global rare neurodegenerative disease treatment market has been divided into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment accounted for the leading share of the market in 2019. Large inventory maintained by hospitals and availability of essential drugs at hospital pharmacies are likely to drive the segment.

Request for Analysis of COVID19 Impact on Rare Neurodegenerative Disease Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78468

Rare Neurodegenerative Disease Treatment Market: Prominent Regions

North America held a major share of the global rare neurodegenerative disease treatment market in 2019. Recent product approvals & launch of new drugs and presence of prominent pharmaceutical companies offering therapeutic products for the treatment of rare neurological disorders are key factors driving the market in the region. Increase in healthcare expenditure also contributes to the growth of the market in North America. Europe held the second largest share of the global rare neurodegenerative disease treatment market in 2019. The growth of the rare neurodegenerative disease treatment market in the region can be attributed to the rise in the number of patients with rare neurological conditions and increase in R&D expenditure.

Buy now Rare Neurodegenerative Disease Treatment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=78468&ltype=S

Rare Neurodegenerative Disease Treatment Market: Key Players

Leading players are expanding their footprint to strengthen their positions in the global rare neurodegenerative disease treatment market. Promising drug candidates in pipeline and increase in research & development efforts by big pharmaceutical companies are likely to present lucrative opportunities in the global rare neurodegenerative disease treatment market. Hence, manufacturers engage in new product development, collaborations, and distribution to gain market share. Key players operating in the global rare neurodegenerative disease treatment market include Allergan plc, Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/prevalence-of-chronic-diseases-that-need-surgical-processes-spurs-sales-in-surgical-drills-market-valuation-to-rise-at-cagr-of-4-7-during-20182026-tmr-301265120.html

https://www.prnewswire.com/news-releases/international-accreditations-for-hospitals-drive-prospects-of-medical-tourism-market-in-offering-quality-patient-care-revenues-to-rise-at-cagr-of-10-5-from-2019-to-2027-tmr-301269941.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

sallowjac · 4 years ago

Link

0 notes

sapanas · 4 years ago

Text

Neurorehabilitation Devices Market 2021: Growth, Industry Size, Demand, Trends, Statistics and 2025 Forecast Report by MRFR

Neurorehabilitation Devices Market Analysis

The neurorehabilitation devices market is anticipated to touch USD 2.25 billion between 2013-2022, states the latest Market Research Future (MRFR) report. Neurorehabilitation devices are therapeutic devices that are utilized in rehabilitation programs. It deals with daunting challenges to learn to live with different neurological conditions including amyotrophic lateral sclerosis, peripheral nervous disorders, spinal cord injuries, brain tremor, multiple sclerosis, Parkinson’s disease, epilepsy, ADHD, and Alzheimer’s disease. Besides, it also assists designers in understanding and better formulating designs, control systems, and measurement for biomedical devices utilized in the treatment.

Various factors are propelling the neurorehabilitation devices market growth. Such factors, as per the latest Market Research Future report, include the proliferation of technologies, especially IoT, AI, and AR and their integration, increasing programs and government funding in the developing regions for supporting research and development activities used for launching new devices, and various technological advancements. Additional factors pushing neurorehabilitation devices market growth include growing robotics and neurorehabilitation wearables, increasing prevalence of neurological diseases worldwide such as Parkinson’s disease, stroke, and multiple sclerosis, improving economic conditions which enable access to improved healthcare and quality care worldwide and changing lifestyle due to industrialization and urbanization.

On the contrary, unavailability of experts to handle neurorehabilitation devices, inadequate disposable income especially in developing economies, absence of personalized home care neurorehabilitation devices, and high costs of the devices are factors that may impede the neurorehabilitation devices market growth during the forecast period.

Neurorehabilitation Devices Market Segmentation

The MRFR report provides an all-inclusive segmental analysis of the neurorehabilitation devices market on the basis of product type, end user, and application.

By product type, the neurorehabilitation devices market is segmented into non-invasive stimulators, brain-computer interface, neuro-robotic devices, wearable devices, and others. Of these, the neuro-robotic devices segment will lead the market over the forecast period.

By end user, the neurorehabilitation devices market is segmented into research institutes, clinics, cognitive care centers, hospitals, and others.

By application, the neurorehabilitation devices market is segmented into Cerebral Palsy, Parkinson’s disease, Schizophrenia, Brain Trauma Injury, Spinal Cord Injury, Stroke, and others.

Neurorehabilitation Devices Market Regional Analysis

By region, the neurorehabilitation devices market report covers the latest trends and growth opportunities across the Asia Pacific, North America, Europe, and the Rest of the World. Of these, North America will dominate the market during the forecast period. Factors pushing the growth of the neurorehabilitation devices market in the region include growing awareness about the perks of using these devices, the presence of developed healthcare infrastructure, rising incidence of neurological disorders, and various technological advancements.

The neurorehabilitation devices market in Europe will have the second-largest share in the market during the forecast period. Factors pushing the growth of the neurorehabilitation devices market in the region include the region’s resurging economy, the proliferation of the healthcare industry, and favorable government initiatives. Germany is the chief contributor in the region.

The global neurorehabilitation devices market in the Asia Pacific region is predicted to have a lucrative growth during the forecast period. Factors pushing the growth of the neurorehabilitation devices market in the region include the wide adoption of neurorehabilitation devices in the region, the presence of leading players, vast development opportunities, and constantly expanding healthcare infrastructure. Japan, India, as well as China are the chief contributors in the region.

The neurorehabilitation devices market in the Rest of the World will have a notable growth during the forecast period.

Obtain Premium Research Report Details @ https://www.marketresearchfuture.com/reports/neurorehabilitation-devices-market-2210

Neurorehabilitation Devices Market Key Players

Notable players profiled in the neurorehabilitation devices market report include Tyromotion, St Jude Medical Inc., Neuro Style, Rehabtronics Inc., Rehab-Robotics Company Limited, Hocoma AG, Medtronic, Bionik Labs, MagVenture A/S, Ekso Bionics, Bioxtreme, Ectron Ltd., Denecor, Bioness, Inc., and Helius Medical Technologies. Key players have incorporated different strategies to stay ahead in the competition, such as research and development activities, joint venture/partnerships, collaborations, new product launches, and more.

Neurorehabilitation Devices Industry News

October 2019: Researchers in China and the US have joined hands to create a soft, stretchable robotic device that comes with a tactile sensory skin that is neurologically integrated.

#Neurorehabilitation Devices Market #Neurorehabilitation Devices Market Size #Neurorehabilitation Devices Market Share #Neurorehabilitation Devices Market Growth

0 notes

wiseguyreportresearch · 4 years ago

Text

Global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market : Market Analysis, Historic Data and Forecast 2020

Attention Deficit Hyperactivity Treatment Disorder

Attention deficit hyperactivity disorder is one of the most common brain disorder characterized by impairing and pervasive symptoms of hyperactivity, inattention, and impulsivity. It is commonly observed in children (<12 years age) as compared to adolescents. It is also known as hyperkinetic disorder/ attention deficit disorder or neuropsychiatric disorder. The exact cause of the Attention Deficit Hyperactivity Disorder (ADHD) is not clear but, expected to be resulted due to genetic factors and environmental influences. It results in improper functioning of the nervous system that led to attention deficit and hyperactivity/impulsiveness condition. The major symptoms include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others. The treatment includes different modalities such as medication, psychotherapy, and education/training.

ALSO READ : https://icrowdnewswire.com/2021/01/06/attention-deficit-hyperactivity-treatment-disorder-adhd-2021-market-estimation-dynamics-outlook-research-trends-and-forecasts-to-2023/

The global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market is growing at a significant CAGR due to changing in lifestyle and systems impacting the quality of the births. Increase in the use of preservatives and additives in children’s diet, an increase in the prevalence of attention deficit hyperactivity disorder among children about 4–17 year age group expected to fuel the growth of attention deficit hyperactivity disorder treatment market over the forecast period. Moreover, increase in the adoption rate of diagnostic guidelines, increasing awareness among patients and physicians about attention deficit hyperactivity disorder treatment are expected to bolster the revenue growth of attention deficit hyperactivity disorder treatment therapeutics market over the forecast period. However, the presence of comorbid conditions in children leads to underdiagnoses of attention deficit hyperactivity disorder treatment, lack of availability of non-stimulant drugs, stringent regulatory guidelines, and a high cost of the medication are expected to hamper the growth of attention deficit hyperactivity disorder treatment market over the forecast period.

ALSO READ : http://www.marketwatch.com/story/covid-19-impact-on-global-risk-analytics-market-analysis-2021---dynamics-trends-revenue-forecast-to-2027-2021-01-29

The global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market is segmented on the basis of medication type, age group, and distribution channel

Based on medication type, the Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market has been segmented into following:

Stimulants

Amphetamines

Methylphenidate

Dextroamphetamine

Dexmethylphenidate

Non-Stimulants

Atomoxetine

Bupropion

Guanfacine

Based on the age group, the Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market has been segmented into following:

Paediatric

Adolescent

Adults

ALSO READ :http://www.marketwatch.com/story/global-application-security-testing-market-projection-by-industry-size-share-movements-by-trend-analysis-growth-status-revenue-expectation-to-2026-2021-01-27

Based on the distribution channel, the Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market has been segmented into following:

Hospital pharmacies

Specialty clinics

Retail pharmacies

Online pharmacies

Nowadays, the global attention deficit hyperactivity disorder treatment market is in a nascent stage, several local and international players are actively involved in the growth of global attention deficit hyperactivity disorder treatment market. Moreover, several natural alternative remedies are available in the market. Launching of new products, collaborations, acquisitions and mergers, and agreements are some of the key strategies followed by various companies to increase their attention deficit hyperactivity disorder treatment market share. For instance, in August 2011, MonoSol Rx, was partnered again with KemPharm to develop a second oral film product to treat attention deficit hyperactivity disorder treatment. Similarly, in May 2013, NeuroSigma received Health Canada approval for its Monarch eTNS System for the treatment of the major depressive disorder and drug-resistant epilepsy, and attention deficit hyperactivity disorder. Approval for new products from various regulatory bodies such as U.S. Food and Drug Administration also fuel the growth of the attention deficit hyperactivity disorder treatment market. For instance, in September 2010, Actavis receives FDA approval of Atomoxetine HCl Capsules for the treatment of attention deficit hyperactivity disorder. Entering of generics into the market, and patent expiries are some key factors drive the attention deficit hyperactivity disorder treatment market growth over the forecast period.

ALSO READ : http://www.marketwatch.com/story/solar-electric-power-generation-market-2021-global-trend-segmentation-and-opportunities-forecast-2027-2021-01-23

Globally, the attention deficit hyperactivity disorder treatment market has been segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the largest share in global attention deficit hyperactivity disorder treatment market followed by Europe and Asia-Pacific. North America holds the largest share attributed to rising prevalence of attention deficit hyperactivity disorder, low threshold of diagnosis is expected to boost the of attention deficit hyperactivity disorder treatment therapeutics market in North America region over the forecast period. Moreover, increase in healthcare expenditure, ongoing clinical trials, early approval of drugs in the U.S., favourable insurance policies for brain monitoring technologies, and technological advancement for the treatment might fuel the attention deficit hyperactivity disorder treatment market. Europe accounts for the significant share attributed to increase in the population, rising prevalence of attention deficit hyperactivity disorder patients, and increased in research and development for the innovation of new products. Asia-Pacific holds a dominant share in attention deficit hyperactivity disorder treatment market owing to developing healthcare infrastructure, government initiatives, a rise in population, and an increase in the number of mental disorders. Japan is the key region in attention deficit hyperactivity disorder treatment market owing to increase in the prevalence of attention deficit hyperactivity disorder among children which is approximately 7.7 %.

Some of the key players in the global attention deficit hyperactivity disorder treatment market are Neos Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Supernus Pharmaceuticals, Inc. (U.S.),Shire plc (Ireland), MonoSol Rx(U.S.), KemPharm, Inc. (U.S.), Neurosigma, Inc. (U.S.) and Actavis (U.S.) to name a few.

In June 2017, Shire Plc received U.S. FDA approval for a long-acting attention-deficit drug Adderall XR aimed at adolescents and adults

In December 2015, Pfizer received U.S. Food and Drug Administration approval of Quillichew ER for attention deficit hyperactivity disorder treatment

Report Outline:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor’s overview, key findings and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup’s details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

ALSO READ : http://www.marketwatch.com/story/casual-wear-market-global-market-by-production-manufacturer-revenue-analysis-and-forecast-to-2025-2021-01-19

0 notes

marketreport · 4 years ago

Text

Behavioural Health Market is Expected to Expand at a CAGR of 3.4% by 2028 End

According to the latest market report published by Future Market Insights titled "Behavioural Health Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028", the global behavioural health market is expected to expand at 3.4% CAGR over the forecast period 2018-2028.

North America is expected to hold the highest revenue share in the global behavioural health market over the forecast period. Currently, over 43.8 million adults in the U.S. are suffering from mental illness, which is fuelling demand for behavioral health services. Developing economies are witnessing large demand for home care services, day care services, and internet-counselling services, which is further expected to boost revenue growth of the behavioural health market in emerging markets.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5375

Global Behavioural Health Market: Segmental Analysis & Forecast

The global behavioural health market is segmented based on service type, disorder type, and region. Based on service type the market is segmented into outpatient counselling, intensive case management, home-based treatment services, inpatient hospital treatment, emergency mental health service and others. The inpatient hospital treatment services type segment is expected to represent highest revenue share in the global behavioural health market. Home-based treatment services are expected to gain popularity among people in the coming years and this segment is expected to expand at a CAGR of 4.0% over the forecast period.

Based on disorder type the market is segmented into the anxiety disorder, bipolar disorder, depression, eating disorder, post-traumatic stress disorder (PSTD), substance abuse disorder and others. Among all disorder types, the anxiety disorder segment is anticipated to continue to lead the global behavioural health market due to a high patient pool globally and high adoption of behavioural health therapy among patients suffering from anxiety issues. According to the WHO, globally 260 million people are suffering from anxiety disorder.

Preview Analysis On Behavioural Health Market Segmentation By Service type- Outpatient Counselling, Intensive Case Management, Home-based Treatment Services, Inpatient Hospital Treatment, Emergency Mental Health Service, Others; Disorder- Anxiety Disorder, ADHD, Bipolar Disorders, Depression, Eating Disorder, Post-traumatic Stress Disorder (PSTD), Substance Abuse Disorder: https://www.futuremarketinsights.com/reports/behavioral-health-market

Increased exposure to drugs and alcohol among young adults and strengthening insurance coverage policies for mental health are identified as key trends among end users in the global behavioural health market. Furthermore, rehabilitation programs for substance abuse disorder patients, outpatient counselling for ADHD affected children, and campaigns to spread awareness regarding mental disorders and drug addiction, etc. are some of the major factors that are driving the growth of the global behavioural health market. Government initiatives to reduce the burden of mental illness and rehabilitation services by non-government organizations (NGO) are further expected to positively impact revenue growth of the global behavioural health market.

Global Behavioural Health Market: Competition Analysis

The global market for behavioural health is fragmented with many local and regional level players operating in the worldwide market. Some of the key players featured in the global behavioural health market report include Acadia Healthcare Co., Inc., Universal Health Services Inc., Magellan Health Inc., National Mentor Holdings Inc., Behavioral Health Services Inc., Behavioral Health Network Inc., North Range Behavioral Health, Strategic Behavioral Health LLC, Seton Healthcare Family (Ascension Health) and Ocean Mental Health Services Inc. etc. among others.

Request Report TOC @ https://www.futuremarketinsights.com/askus/rep-gb-5375

More from Healthcare, Pharmaceuticals and Medical devices:

Laboratory Information Systems Market Segmentation By End User - Hospitals, Clinics, Independent Laboratories And Others; By Component - Software, Services And Hardware; By Delivery Mode - On-Premises And Cloud Based; By Key Regions - North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan, Japan And Middle East & Africa: https://www.futuremarketinsights.com/reports/laboratory-information-systems-market

Bone Growth Stimulators Market Segmentation By Product - Invasive Bone Growth Stimulators, Non-Invasive Bone Growth Stimulators and Ultrasound Bone Growth Stimulators; By End User - Hospital, Ambulatory Surgical Centers, Orthopedic Clinics, and Home Care; By Application - Trauma Injury and Fractures, Spinal Fusion, and Osteogenesis; Others - Market Size, Growth, Forecast, Sales, Pricing Forecast, Share, Export Value, Export Volume, Trade: https://www.futuremarketinsights.com/reports/bone-growth-stimulators-market

Peptide therapeutics market segmentation by disease indication - cancer, cardiovascular, central nervous system, metabolic, infection, gastrointestinal, dermatology, respiratory, endocrinology; by route of administration - parenteral, mucosal, oral, transdermal; by drug type - branded, generic: https://www.futuremarketinsights.com/reports/peptide-therapeutics-market

0 notes

shruticmi · 4 years ago

Text

The Global Vetiver Oil Market to surpass at US$ 56.34 million in 2016.

Summary: The Global Vetiver Oil Market is expected to exhibit a CAGR of 13.71%,during 2017 – 2025.

Market review:

Vetiver oil helps patients suffering from muscular aches, arthritis, gout, and rheumatism.The growing use of vetiver oil in medical applications is expected to fuel Global Vetiver Oil market growth over the forecast period.The chemical composition of the product and its solubility in alcohol is expected to improve its miscibility, thereby, making it a unique ingredient in perfumes.

The oil’s soothing and calming aroma has led to its increased adoption as a complementary treatment for anxiety, depression, and other mental health disorders, including ADHD and PTSD. Among applications, the pharmaceutical segment is expected to be the fastest growing segment in the market, owing to its sedative, nervine, and antiseptic properties.

Download the PDF Brochure on Global Vetiver Oil Market here

Market Opportunities:

Vetiver oil is extensively utilized in the perfume industry for manufacturing incense, scents and colognes. Increasing personal grooming trend owing to rising disposable incomes would propel vetiver oil market growth.

Vetiver oil owing to its therapeutic and anti-anxiety properties is used in diffusers which helps to improve breathing problems. The product is used for treating attention deficit hyperactivity disorder in children and teenagers. Increasing investments in R&D activities leading to product innovation along with rising natural products demand will propel vetiver oil market demand.

Competitive Landscape

Major players operating in the global vetiver oil market include International Fragrance and Flavor Inc., Lluch Essence SL, UniKode S.A., Frager S.A., Robertet Group, Ernesto Ventos S.A., Floracopeia Inc., Fleurchem Inc., and Haiti Essential Oil Co. S.A.

Market Segmentation:

By Product

· Organic

· Conventional

By Application

· Pharmaceuticals

· Personal Care & Cosmetics

· Food & Beverages

· Fragrances

· Aromatherapy

· Cleaning & Homecare

Regional Analysis

· North America

· Asia Pacific

· Central America

· South America

· Middle East & Africa

Buy Now the Research Report on Global Vetiver Oil Market